Coherus Looks To Galvanize Pegfilgrastim Biosimilar With New Formats
California-Based Firm Updates On Planned Novel Autoinjector Presentation
Coherus BioSciences spoke at length about its two marketed biosimilars, referencing Neulasta and Lucentis, during the company’s first-quarter earnings call.
You may also be interested in...
Coherus BioSciences offered clarity and insight into its three marketed biosimilar products, as the firm continues to await USFDA approval for its pegfilgrastim biosimilar using an on-body injector device.
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.